Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 901–968 of 968
de la Noue, V. D. V., Tubiana, S., Rontani, M., Giry, M., Sarton, B., Pommier, J., Terzi, N., Jozwiak, M., Argaud, L., Dupuis, C., et al. (2026) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2026.04.007
Self-citationMa, H., Wang, S., DANG, Z., Xie, W., Li, N., Li, J., Yang, Y., & Jin, Z. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2690139
Mineralocorticoid magic? Evaluating fludrocortisone in septic shock
Tran, N., Ragoonanan, D., Posgai, L., Noble, M., & Cummings, J. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70638
Heming, N., Baron, Ė., Müller, G., Badie, J., Préau, S., Siami, S., Pouplet, C., Berger, A., Damoisel, C., Argaud, L., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119187
Self-citationMugada, V. K., Saragadam, G. R. P., Rajana, A., & Arikitamula, R. (2026) · Prague Medical Report · doi:10.14712/23362936.2026.12
Bourdiol, A., Bruder, N. J., Dépret, F., Duchaussoy, D. F., Flet, L., Fortin, J., Gaufichon, A.-E., Glavnik, B., Jeanne, M., Jobert, A., et al. (2026) · Trials · doi:10.1186/s13063-026-09869-z
“There is growing evidence from other areas of critical care medicine—such as septic shock [4], community-acquired pneumonia (CAP) [5], and ARDS [6] that low-to-moderate doses of corticosteroid therapy improves clinical outcomes, including time to recovery and mortality.”
Self-citationEastwood, B., Terrington, I., Young, R. K., Cox, O., Webb, E., Mckenzie, C., Saeed, K. B. A., Morris, A. C., Grocott, M. P. W., & Dushianthan, A. (2026) · European Respiratory Review · doi:10.1183/16000617.0259-2025
“Trials in septic shock suggest that hydrocortisone both alone and in combination with fludrocortisone can lead to faster shock reversal [109, 114, 115].”
Fludrocortisone in septic shock: revisiting the potential role of mineralocorticoid supplementation
Nguyen, T. L. (2026) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000203
Chang, W.-H., Wu, W.-J., Shen, H.-F., & Hu, T.-Y. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13907-1
Hydrocortisone Use for Septic Shock in Patients With CKD
Dhamelia, P. M., Abeyagunawardene, H., Kore, R. A., Raghavan, D., Arthur, J. M., Vyas, K. S., Khandekar, N., & Jain, N. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106686
Pérez, I., Paredes, M. C., Barajas, O. L. T., & Sánchez, A. (2026) · Medicina Crítica · doi:10.35366/123477
Lac, J., Han, S., Ahmad, M., Starey, H., Ganguly, S., Tett, M., Adeyemi, O., Bray, J. J. H., Ahmad, M. T., & Providencia, R. A. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003934
Carpenter, S. L., & Coopersmith, C. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_26
The Endocrine Axis and Critical Illness
Kim, S. S., & Saillant, N. N. (2026) · Springer eBooks · doi:10.1007/978-3-032-22660-0_33
An International Survey of Corticosteroid Use in Septic Shock
Ho, J. C., Zamir, N., Pereira, T. V., Rochwerg, B. N., Bosch, N. A., Mazer, C. D., Kaufman, D. A., Yarnell, C. J., Law, A. C., Jivraj, N. K., et al. (2026) · CHEST Critical Care · doi:10.1016/j.chstcc.2026.100297
Fludrokortison im septischen Schock
Schmoch, T., & Brenner, T. (2026) · Die Anaesthesiologie · doi:10.1007/s00101-026-01712-z
“Die in dieser Ausgabe von JosefBriegel vorgelegte Übersichtsarbeit veranschau-licht die vorhandene Evidenz so klar und unmissverständlich wie selten zuvor: Auf der einen Seite zeigen zwei prospektive multizentrische Doppelblindstudien aus Frankreich [3, 4] eine signifikante Senkung der 28-bzw.”
Hydrokortison beim septischen Schock: Mit oder ohne Fludrokortison?
Briegel, J. (2026) · Die Anaesthesiologie · doi:10.1007/s00101-026-01711-0
Sepsis-Induced Cardiomyopathy and Acute Respiratory Distress Syndrome
Bikram, O., Gabriel, E., & Yuri, M. (2026) · Cardiovascular Science · doi:10.70322/cvs.2026.10011
Five things the intensivist cannot forget in the management of septic shock
Pontes, C. D. N., Estenssoro, E., & Machado, F. R. (2026) · Critical Care Science · doi:10.62675/2965-2774.20260360
Ayvat, P. U., Sezak, N., Bilek, G., Ayvat, A. G., Çolakoğulları, M., ALPAĞUT, G. Ş., Ömeroğlu, Ş. K., & Koca, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155969
“…controlled trials, which demonstrated that while moderate-dose hydrocortisone accelerates shock reversal and increases vasopressor-free days, its impact on ultimate all-cause binary mortality reduction varies depending on baseline patient case-mix and the severity of systemic shock [30,31].”
Síndrome vasopléjico en cirugía cardíaca
Longo, S., Giaj-Merlera, A., Bertazzo, B., Orlando, F., Cassineri, A., & Banille, E. (2026) · Revista Chilena de Anestesia · doi:10.25237/revchilanestv55n4-06
Gestion des immunosuppresseurs chez les transplantés rénaux en réanimation
Berardi, M., Pham, T. O., Snanoudj, R., Monnet, X., Carpentier, C., & Zaidan, M. (2026) · Médecine Intensive Réanimation · doi:10.37051/mir-34-002267
Geroteo, J. S., Dauger, S., & Levy, M. (2026) · EMC - Médecine d urgence · doi:10.1016/s1959-5182(26)41791-2
Dumargne, H., Ly, S. H., Louzier, V., Allaouchiche, B., Hammed, A., & Dargent, A. (2026) · Critical Care · doi:10.1186/s13054-026-06160-0
Self-citationAbbas, H., & Ahmed, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-28643-7_8
Steroids in severe scrub typhus infection: a retrospective cohort study
Bose, P., Atul Ramchandra, M. O. R. E., Dhanawade, V. S., Peter, J. V., Loganathan, S., Samuel, P., George, K., Chandiraseharan, V. K., Lenin, A., Hansdak, S. G., et al. (2026) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2026.1906165
Cardiovascular adrenoceptors physiology in patients with shock
Jozwiak, M., Singer, M., & Annane, D. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08589-x
Self-citationDiscordant Evidence on Corticosteroids in Sepsis: A Meta-Research StudyPreprint
Weibel, S., Duengfelder, H., Pscheidl, T., Krone, M., & Meybohm, P. (2026) · medRxiv · doi:10.64898/2026.08.20.26360343
Rad, N. K., Lakzaei, T., Nakhostin, M., & Soltanmohammadi, S. (2026) · Pneumonia · doi:10.1186/s41479-026-00209-y · Cited by 1
Rhee, C., Masur, H., Klompas, M., Bell, T. D., Busch, L. M., Chiotos, K., Classen, D., Gilbert, D., Heil, E. L., Hou, C. H. Y., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag438 · Cited by 1
A Comparative Analysis of Aging Across Causes of Death
Sorci, G., & Faivre, B. (2026) · Evolutionary Applications · doi:10.1111/eva.70316
Fadel, O. E., Nguyen, T., Modzelewski, K. L., Ferri, G. M., Anderson, R., Bosch, N. A., & Davis, D. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-69412-7
Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock
Ibrahim, J., Shakoor, I., Abbas, S. S., Kauser, N., Syed, S., & Ibrahim, T. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i4.3369
Duclos, G., Boucékine, M., Tabah, A., Ruckly, S., Buetti, N., Timsit, J., Léone, M., EUROBACT-2 Study Group, ESICM, ESGCIP, E., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0356721
Self-citationBeyond Antibiotics: A Practical Guide to Host-Directed Therapy in Severe Infections
Ahmed, W. A., Qutub, D. M., Alzahrani, O. J. M., & Alsharif, H. (2026) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2026.179019
Neumann, C. M., Hickl, F., Kemnitzer, J., Leitner, M., Giamarellos‐Bourboulis, E. J., & Rubio, I. (2026) · Critical Care · doi:10.1186/s13054-026-06315-z · Cited by 1
Kwon, S., Kwak, S. G., & Hong, H. (2026) · Journal of Critical Care · doi:10.1016/j.jcrc.2026.155750
Reddi, B. A. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-31459-8_2
Corticosteroid therapy in cardiogenic shock: A systematic review and meta-analysis
Zwengunde, C., White, L., Campbell, D. I., Lahlou, A., Buckel, M., McGuigan, P. J., Proudfoot, A. G., & Warren, A. (2026) · Journal of the Intensive Care Society · doi:10.1177/17511437261483562
Septic shock in the era of precision medicine: rethinking fluids, vasopressors, and immunomodulation
Du, J., Feng, H., Dong, S., Yang, C., Al-Danakh, A., & Zhou, S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1909143
“Large randomized trials differed in their survival findings: ADRENAL found no significant reduction in 90-day mortality but faster shock resolution, whereas APROCCHSS reported lower 90-day mortality with hydrocortisone plus fludrocortisone (85, 86).”
Stress, Allostase und Organversagen
Bauer, M. W., & Wetzker, R. (2026) · Die Anaesthesiologie · doi:10.1007/s00101-026-01735-6
Sepsis in the Emergency Department: An Evidence-Based Reappraisal of the “Golden Hour”
Danış, F., & Kudu, E. (2026) · Anatolian Journal of Emergency Medicine · doi:10.54996/anatolianjem.1972015
Aspide, R., & Biasucci, D. G. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100503
“Large randomized controlled trials (RCTs), such as ADRENAL [15] and APROCCHSS [16], showed different effects of corticosteroid therapy across trials.”
Long, E., Nolan, G., Williams, A. J., Jani, S., Craig, S. S., Kochar, A., Borland, M. L., Phillips, N. T., George, S., Dalziel, S. R., et al. (2026) · Archives of Disease in Childhood · doi:10.1136/archdischild-2025-330072
Alonso‐Carrillo, J., Pinacho, M. O., Latre, M. C., Ruiz‐Ruigómez, M., Lumbreras, C., & Lalueza, A. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1916526
Toppin, P. J., Correia, M. D. T., Chang, Y., Adhikari, L., McLaverty, B. P., & Natarajan, A. (2026) · Intensive Care Medicine Experimental · doi:10.1186/s40635-026-00972-8
Hu, Q., Jiang, J., Zhu, H., Zhenzhu, Y., Tang, S., Li, H., Feng, W., Zeng, X., Huang, X., Huang, H., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1818444
Karancı, Y., Çiyiltepe, F., Akcin, G., & Beggi, H. (2026) · Journal of Clinical Monitoring and Computing · doi:10.1007/s10877-026-01516-x
沈佳伟, Sun, C., Wang, G., Zhao, X., Li, S., & Zhu, F. (2026) · Journal of Clinical Monitoring and Computing · doi:10.1007/s10877-026-01513-0
Luo, H., Lin, J., Shen, H., Huang, D., Ling, M., & Ye, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1925322
“Corticosteroids have an established adjunctive role in selected patients with septic shock and an ongoing vasopressor requirement (Annane et al., 2018; Venkatesh et al., 2018; Evans et al., 2021), whereas cytokine-targeted strategies directed against TNF-α , IL-1, or IL-6 have not produced…”
Jia, Z., Zhao, X., Liu, X., & 李小丽 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1962609
“…reduction that could be accelerated after shock resolution; ADRENAL continued treatment for up to 7 days or until death or intensive care unit discharge; and APROCCHSS used a fixed 7-day course without tapering (Sprung et al., 2008; Venkatesh et al., 2018; Annane et al., 2018; Gordon et al., 2016).”
InfluentialKoca, H., & Ayvat, P. U. (2026) · Infection · doi:10.1007/s15010-026-03019-y
Platelet trajectory subphenotypes in intensive care patients with sepsis-induced coagulopathy
Wei, E., Zhao, F., Li, F., & Lu, W. (2026) · Scientific Reports · doi:10.1038/s41598-026-65712-0
Antcliffe, D. B., Uhle, F., Marshall, D. C., Green, A. D., Gordon, A. C., & Forni, L. G. (2026) · Critical Care Explorations · doi:10.1097/cce.0000000000001496
Liu, Z., Quek, R. F., Cheng, J. L. K., Goh, J. S. R., Kwek, G. G. J., Koh, S. H., Zhang, Z., Fook-Chong, S. M. C., Lam, S. W., & Ong, M. E. H. (2026) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.26.317
Marella, P., Alizadehsani, R., Laupland, K. B., Keogh, S. J., Edwards, F., White, K., Denny, K. J., Whebell, S., Blank, S., Kumar, A., et al. (2026) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2026.100228
Sepsis: Epidemiology, Pathophysiology, and Management
Pan, G., Deng, Y., Ma, L., Li, Y., Qian, Y., Ma, Y., Rao, H., Zhu, Y., & Yan, P. (2026) · MedComm · doi:10.1002/mco2.71079
“ADRENAL demonstrated faster shock resolution without a significant reduction in 90-day mortality, whereas APROCCHSS reported lower 90-day mortality with hydrocortisone plus fludrocortisone [ 96, 97 ].”
Endo, A., Yamakawa, K., Tagami, T., Yamamoto, R., Umemura, Y., Takayama, W., Hoshi, H., Hayashi, Y., Komori, A., Yanagisawa, T., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-126112
Ruwisch, J., Buhlmann, A., Wild, L., Wendel‐Garcia, P. D., Pape, T., Hofmaenner, D. A., Putensen, C., Kruse, P., Holtgrave, G.-H., Schenk, H. J., et al. (2026) · Intensive Care Medicine Experimental · doi:10.1186/s40635-026-00984-4
Acute-on-chronic liver failure: A global multisociety consensus on definitions*
European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), Asia-Pacific Association for the Study of the Liver (APASL), Latin American Association for the Study of the Liver (ALEH), & Society on Liver Disease in Africa (SOLDA) (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102453
Acute-on-chronic liver failure: a global multisociety consensus on definitions
Shawcross, D. L., Angeli, P., Shawcross, D. L., Moreno, C., Moreau, R., Wendon, J. A., Fernández, J., Trebicka, J., Angeli, P., Tonon, M., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11169-2
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Angeli, P., Bajaj, J. S., Bahri, A. K., Castro, G. E., Choudhury, A. K., Debzi, N., Elkin, B. R., El-Kassas, M., Farias, A. Q., Fernández, J., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.09.005
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Society on Liver Disease in Africa (SOLDA) (2026) · Hepatology · doi:10.1097/hep.0000000000001891
Dean, R., Fairman, W., Liao, J., & Wibbenmeyer, L. A. (2026) · Journal of Burn Care & Research · doi:10.1093/jbcr/irag181
Cosenza, G., Fiore, M., Giurazza, R., Pota, V., Coppolino, F., Sansone, P., & Pace, M. C. (2026) · Biomedicines · doi:10.3390/biomedicines14112518
Xie, S., Tian, H., Song, Y., & Liang, F.-X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1960543
Chang, Y., Chung, C.-F., Lee, S.-H., Tsai, M., Chang, Y.-P., Wu, C.-C., & Huang, K.-T. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04211-7
Wu, Z., Yao, T., & Shen, N. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117640
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.